Telix Expands Prostate Cancer Activity with GenesisCare Collaboration
Telix releases details of two ancillary studies under the ProstACT program, including a Phase II study in collaboration with GenesisCare.
Telix and Merck to Commence Pan-Cancer Clinical Combination Studies
Telix announces pan-cancer clinical collaboration with Merck KGaA, Darmstadt, Germany.
Two New Studies to Explore Telix Assets in Breast Cancer Theranostics
Telix announces two new studies to evaluate the potential utility of TLX591-CDx and TLX250-CDx in breast cancer.
Telix Progresses Novel Lung and Ovarian Cancer Theranostic APOMAB®
Telix extends partnership with AusHealth relating to APOMAB®, a novel theranostic being investigated in lung and ovarian cancers
Telix’s TLX66 in Phase II Academic Study of Pediatric Leukemia
Telix announces Phase II academic study of TLX66 in children with high-risk leukemia.
Telix H1 2021 Results and Company Update Conference Call
Telix to hold investor conference call to present H1 2021 financial results and Company update.
Mr. Ryoichi Tanaka Joins Telix Japan as Chief Operating Officer
Telix is delighted to announce that Ryoichi Tanaka has joined the Japan business as Chief Operating Officer and Head of Business Development.
First Patient Dosed in CUPID Study of Telix’s Targeted Alpha Therapy Candidate for Prostate Cancer
Telix announces the first patient has been dosed in its ‘CUPID’ Phase I study of TLX592 in patients with advanced prostate cancer.
Ms. Helen Hovenga Joins Telix as Chief People Officer
Telix is delighted to announce that Ms. Helen Hovenga has joined the Telix executive team in the role of Chief People Officer.
Telix Seneffe Production Facility: Progress Update
Telix authorised to decommission first of two cyclotrons at Seneffe radiopharmaceutical production facility.